Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Government Contract Win

28 Feb 2013 07:00

RNS Number : 8492Y
Instem plc
28 February 2013
 

28 February 2013

 

Instem plc

("Instem", or, the "Company")

 

US Government Contract Win

 

Provantis Preclinical Software Chosen for National Toxicology Program by National Institute of Environmental Health Sciences

 

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, announced today that the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health (NIH), has purchased the Provantis 9® preclinical software suite via SaaS (Software-as-a-Service) to support National Toxicology Program studies. These Reproductive, Immunotox, Neurobehavioural, Sensitisation and Carcinogenicity studies are primarily carried out at contractor laboratory sites throughout the United States.

 

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further 9 years, giving a possible total contract value for all 10 years of between $6.2m-$7.6m. The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in further material increase in revenue.

 

The National Toxicology Program (NTP) is an interagency program established in 1978 to coordinate toxicology research and development across the Department of Health and Human Services. The program was also created to strengthen the science base in toxicology, develop and validate improved testing methods and provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public.

 

Headquartered at NIEHS, the NTP is managed by the NIEHS and supported by the United States Food and Drug Administration and the Centers for Disease Control and Prevention.

 

Phil Reason, CEO of Instem plc, commented, "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices. Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations, The accessibility of Provantis data will also enable the National Institute of Environmental Health Sciences to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

 

"This long term contract will also provide funding for the development of the Provantis suite in areas specific to the National Toxicology Program, adding further depth to our market leading study management platform and positioning Instem well for anticipated contract extensions and any similar future projects."

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

 

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

 

 

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, Australia, China, India, Singapore and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

About NIEHS

The NIEHS supports research to understand the effects of the environment on human health and is part of the National Institutes of Health (NIH). Its mission is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

 

For more information on environmental health topics, visit www.niehs.nih.gov.

 

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 

This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27320130004C.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDXGDDSBDBGXR
Date   Source Headline
26th Jan 20073:07 pmRNSAcquisition of stake in INS
18th Dec 20063:09 pmRNSTotal Voting Rights
26th Sep 20067:00 amRNSInterim Results
30th Aug 20064:05 pmRNSNotice of Results
17th Jul 20063:21 pmRNSRe Contract
27th Jun 20063:53 pmRNSDirectors Dealings
6th Jun 20062:47 pmRNSDirector/PDMR Shareholding
5th Jun 20063:51 pmRNSHolding(s) in Company
2nd Jun 20064:49 pmRNSDirectors. dealings
2nd Jun 20064:48 pmRNSDirectors. dealings
1st Jun 20067:01 amRNSSellafield Agreement
31st May 200610:48 amRNSFirst Day of Dealings
4th Aug 20059:39 amRNSCompulsory Acquisition
29th Jul 200511:38 amRNSHolding(s) in Company
8th Jul 20054:36 pmRNSBoard Changes and Delisting
8th Jul 20057:00 amRNSOffer for Infast Group Update
6th Jul 20057:01 amRNSOffer for Infast Group Update
28th Jun 20055:27 pmRNSOffer for Infast Group Update
20th Jun 20057:01 amRNSOffer for Infast Group Update
31st May 20054:30 pmRNSRule 8.4- Infast Group PLC
31st May 20059:57 amRNSRule 8.3- Infast Group PLC
27th May 20055:12 pmRNSOffer Document Posted-Amend
27th May 20053:58 pmRNSOffer Document Posted
26th May 20057:02 amRNSRecom. Offer for Infast Group
10th May 200512:48 pmRNSEPT Disclosure
9th May 200510:32 amRNSEPT Disclosure
4th May 200511:06 amRNSEPT Disclosure
29th Apr 200510:31 amRNSResult of AGM
28th Apr 20058:45 amRNSAGM Statement
26th Apr 200511:42 amRNSEPT Disclosure
26th Apr 200511:16 amRNSRule 8.3- Infast Group PLC
25th Apr 200512:00 pmRNSEPT Disclosure
22nd Apr 200511:25 amRNSEMM Disclosure
21st Apr 20053:36 pmRNSDisposal
20th Apr 200510:27 amRNSEMM Disclosure
14th Apr 20059:40 amRNSRule 8 - Infast Group PLC
13th Apr 20053:00 pmRNSRule 2.10 Announcement
13th Apr 200512:20 pmRNSStatement re Possible Offer
12th Apr 200510:04 amRNSHolding(s) in Company
8th Apr 20052:19 pmRNSHolding(s) in Company
7th Apr 20055:12 pmRNSHolding(s) in Company
3rd Mar 20057:01 amRNSFinal Results
15th Feb 20052:32 pmRNSDisposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.